0

Close
 
Upcoming Allied Market Research
2023
Cold Remedies Market

Cold Remedies Market

by Drug Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Others), by Dosage Type (Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Supermarkets/Hypermarkets, e-Commerce/Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03245
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cold Remedies Market

Request Now !

Cold is an infectious disease that affects the respiratory system. The common symptoms for cold include sneezing, sore throat, a stuffy nose, and coughing. Cold remedies are used to treat cold in immunosuppressed individuals. The composition of many cold medicines are same and therefore taking too much of certain medication can lead to drug resistance or serious injury.

Rise in geriatric population, demand for effective combination products, and switch from Rx to OTC category drive the market. However, competition faced by international players due to drugs from local manufacturers and natural remedies restrain the market growth. Favorable regulations and opportunities in the emerging economies of Asia-Pacific and LAMEA due to availability of large patient pools provide growth prospects for the market.

The report segments the global cold remedies market based on drug type, dosage type, end user, and region. Based on drug type, it is divided into antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Based on dosage type, it is classified into oral syrups, tablets/pills, nasal drops, lozenges, and others.

By distribution channel, it is categorized into hospital pharmacies, retail pharmacies, drug stores, supermarkets/hypermarkets, and e-commerce/online pharmacies. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players operating in the market include Reckitt Benckiser Group plc, Johnson & Johnson, GlaxoSmithKline plc, Novartis AG, Bayer AG, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Prestige Brands Holdings, Inc., and Procter & Gamble Co.

Key Benefits

  • The study provides an in-depth analysis of the global market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Competitive intelligence highlights the business practices followed by leading players across various regions.
  • Comprehensive analysis of all geographic regions are provided that helps determine the prevailing opportunities in these regions.
  • Key market players within the market are profiled in the report and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.
  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

 Cold Remedies Market Report Highlights

Aspects Details
By Drug Type
  • Antihistamines
  • Expectorants
  • Bronchodilators
  • Decongestants
  • Antibiotics
  • Others
By Dosage Type
  • Oral Syrups
  • Tablets/Pills
  • Nasal Drops
  • Lozenges
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Supermarkets/Hypermarkets
  • e-Commerce/Online Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Reckitt Benckiser Group plc, AstraZeneca plc, Johnson & Johnson, GlaxoSmithKline plc, Prestige Brands Holdings, Inc., Bayer AG, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Procter & Gamble Co.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: COLD REMEDIES MARKET, BY DRUG TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Type

    • 4.2. Antihistamines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Expectorants

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Bronchodilators

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Decongestants

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Antibiotics

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: COLD REMEDIES MARKET, BY DOSAGE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Dosage Type

    • 5.2. Oral Syrups

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Tablets/Pills

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Nasal Drops

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Lozenges

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: COLD REMEDIES MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Drug Stores

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Supermarkets/Hypermarkets

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. E-Commerce/Online Pharmacies

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: COLD REMEDIES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Type

      • 7.2.3. Market Size and Forecast, By Dosage Type

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Cold Remedies Market

        • 7.2.6.1. Market Size and Forecast, By Drug Type
        • 7.2.6.2. Market Size and Forecast, By Dosage Type
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Cold Remedies Market

        • 7.2.7.1. Market Size and Forecast, By Drug Type
        • 7.2.7.2. Market Size and Forecast, By Dosage Type
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Cold Remedies Market

        • 7.2.8.1. Market Size and Forecast, By Drug Type
        • 7.2.8.2. Market Size and Forecast, By Dosage Type
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Type

      • 7.3.3. Market Size and Forecast, By Dosage Type

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Cold Remedies Market

        • 7.3.6.1. Market Size and Forecast, By Drug Type
        • 7.3.6.2. Market Size and Forecast, By Dosage Type
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Cold Remedies Market

        • 7.3.7.1. Market Size and Forecast, By Drug Type
        • 7.3.7.2. Market Size and Forecast, By Dosage Type
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Cold Remedies Market

        • 7.3.8.1. Market Size and Forecast, By Drug Type
        • 7.3.8.2. Market Size and Forecast, By Dosage Type
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Cold Remedies Market

        • 7.3.9.1. Market Size and Forecast, By Drug Type
        • 7.3.9.2. Market Size and Forecast, By Dosage Type
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Cold Remedies Market

        • 7.3.10.1. Market Size and Forecast, By Drug Type
        • 7.3.10.2. Market Size and Forecast, By Dosage Type
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Cold Remedies Market

        • 7.3.11.1. Market Size and Forecast, By Drug Type
        • 7.3.11.2. Market Size and Forecast, By Dosage Type
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Cold Remedies Market

        • 7.3.12.1. Market Size and Forecast, By Drug Type
        • 7.3.12.2. Market Size and Forecast, By Dosage Type
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Type

      • 7.4.3. Market Size and Forecast, By Dosage Type

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Cold Remedies Market

        • 7.4.6.1. Market Size and Forecast, By Drug Type
        • 7.4.6.2. Market Size and Forecast, By Dosage Type
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Cold Remedies Market

        • 7.4.7.1. Market Size and Forecast, By Drug Type
        • 7.4.7.2. Market Size and Forecast, By Dosage Type
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Cold Remedies Market

        • 7.4.8.1. Market Size and Forecast, By Drug Type
        • 7.4.8.2. Market Size and Forecast, By Dosage Type
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Cold Remedies Market

        • 7.4.9.1. Market Size and Forecast, By Drug Type
        • 7.4.9.2. Market Size and Forecast, By Dosage Type
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Cold Remedies Market

        • 7.4.10.1. Market Size and Forecast, By Drug Type
        • 7.4.10.2. Market Size and Forecast, By Dosage Type
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Cold Remedies Market

        • 7.4.11.1. Market Size and Forecast, By Drug Type
        • 7.4.11.2. Market Size and Forecast, By Dosage Type
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Cold Remedies Market

        • 7.4.12.1. Market Size and Forecast, By Drug Type
        • 7.4.12.2. Market Size and Forecast, By Dosage Type
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Cold Remedies Market

        • 7.4.13.1. Market Size and Forecast, By Drug Type
        • 7.4.13.2. Market Size and Forecast, By Dosage Type
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Cold Remedies Market

        • 7.4.14.1. Market Size and Forecast, By Drug Type
        • 7.4.14.2. Market Size and Forecast, By Dosage Type
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Type

      • 7.5.3. Market Size and Forecast, By Dosage Type

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Cold Remedies Market

        • 7.5.6.1. Market Size and Forecast, By Drug Type
        • 7.5.6.2. Market Size and Forecast, By Dosage Type
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Cold Remedies Market

        • 7.5.7.1. Market Size and Forecast, By Drug Type
        • 7.5.7.2. Market Size and Forecast, By Dosage Type
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Cold Remedies Market

        • 7.5.8.1. Market Size and Forecast, By Drug Type
        • 7.5.8.2. Market Size and Forecast, By Dosage Type
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Cold Remedies Market

        • 7.5.9.1. Market Size and Forecast, By Drug Type
        • 7.5.9.2. Market Size and Forecast, By Dosage Type
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Cold Remedies Market

        • 7.5.10.1. Market Size and Forecast, By Drug Type
        • 7.5.10.2. Market Size and Forecast, By Dosage Type
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Cold Remedies Market

        • 7.5.11.1. Market Size and Forecast, By Drug Type
        • 7.5.11.2. Market Size and Forecast, By Dosage Type
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Reckitt Benckiser Group Plc

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Johnson And Johnson

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. GlaxoSmithKline Plc

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Novartis AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Bayer AG

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. AstraZeneca Plc

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Sun Pharmaceutical Industries Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Pfizer Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Prestige Brands Holdings, Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Procter And Gamble Co.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COLD REMEDIES MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL COLD REMEDIES MARKET FOR ANTIHISTAMINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL COLD REMEDIES MARKET FOR EXPECTORANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL COLD REMEDIES MARKET FOR BRONCHODILATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL COLD REMEDIES MARKET FOR DECONGESTANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL COLD REMEDIES MARKET FOR ANTIBIOTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL COLD REMEDIES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL COLD REMEDIES MARKET, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL COLD REMEDIES MARKET FOR ORAL SYRUPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL COLD REMEDIES MARKET FOR TABLETS/PILLS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL COLD REMEDIES MARKET FOR NASAL DROPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL COLD REMEDIES MARKET FOR LOZENGES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL COLD REMEDIES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL COLD REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL COLD REMEDIES MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL COLD REMEDIES MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL COLD REMEDIES MARKET FOR DRUG STORES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL COLD REMEDIES MARKET FOR SUPERMARKETS/HYPERMARKETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL COLD REMEDIES MARKET FOR E-COMMERCE/ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL COLD REMEDIES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA COLD REMEDIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. U.S. COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 27. U.S. COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. CANADA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. CANADA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE COLD REMEDIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ITALY COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 45. ITALY COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 46. ITALY COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 52. UK COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. RUSSIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 55. RUSSIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. REST OF EUROPE COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 58. REST OF EUROPE COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC COLD REMEDIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 61. ASIA-PACIFIC COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. CHINA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 64. CHINA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 65. CHINA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. INDIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 70. INDIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 71. INDIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 74. SOUTH KOREA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 79. THAILAND COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 80. THAILAND COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 82. MALAYSIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 83. MALAYSIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 85. INDONESIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 86. INDONESIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA PACIFIC COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA COLD REMEDIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 95. BRAZIL COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 96. BRAZIL COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 99. SOUTH AFRICA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. UAE COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 104. UAE COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 105. UAE COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 107. ARGENTINA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 108. ARGENTINA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA COLD REMEDIES, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA COLD REMEDIES, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 111. REST OF LAMEA COLD REMEDIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
  • TABLE 113. RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
  • TABLE 114. RECKITT BENCKISER GROUP PLC: OPERATING SEGMENTS
  • TABLE 115. RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 116. RECKITT BENCKISER GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 118. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 119. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 120. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 121. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 123. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 124. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 125. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 126. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 128. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 129. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 130. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 131. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. BAYER AG: KEY EXECUTIVES
  • TABLE 133. BAYER AG: COMPANY SNAPSHOT
  • TABLE 134. BAYER AG: OPERATING SEGMENTS
  • TABLE 135. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 136. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 138. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 139. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 140. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 141. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 143. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 144. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 145. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 146. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. PFIZER INC.: KEY EXECUTIVES
  • TABLE 148. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 149. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 150. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 151. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. PRESTIGE BRANDS HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 153. PRESTIGE BRANDS HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 154. PRESTIGE BRANDS HOLDINGS, INC.: OPERATING SEGMENTS
  • TABLE 155. PRESTIGE BRANDS HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 156. PRESTIGE BRANDS HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. PROCTER AND GAMBLE CO.: KEY EXECUTIVES
  • TABLE 158. PROCTER AND GAMBLE CO.: COMPANY SNAPSHOT
  • TABLE 159. PROCTER AND GAMBLE CO.: OPERATING SEGMENTS
  • TABLE 160. PROCTER AND GAMBLE CO.: PRODUCT PORTFOLIO
  • TABLE 161. PROCTER AND GAMBLE CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL COLD REMEDIES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL COLD REMEDIES MARKET
  • FIGURE 3. SEGMENTATION COLD REMEDIES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN COLD REMEDIES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOLD REMEDIES MARKET
  • FIGURE 11. COLD REMEDIES MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 12. COLD REMEDIES MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. COLD REMEDIES MARKET FOR EXPECTORANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. COLD REMEDIES MARKET FOR BRONCHODILATORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. COLD REMEDIES MARKET FOR DECONGESTANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. COLD REMEDIES MARKET FOR ANTIBIOTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. COLD REMEDIES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. COLD REMEDIES MARKET SEGMENTATION, BY BY DOSAGE TYPE
  • FIGURE 19. COLD REMEDIES MARKET FOR ORAL SYRUPS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. COLD REMEDIES MARKET FOR TABLETS/PILLS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. COLD REMEDIES MARKET FOR NASAL DROPS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. COLD REMEDIES MARKET FOR LOZENGES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. COLD REMEDIES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. COLD REMEDIES MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 25. COLD REMEDIES MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. COLD REMEDIES MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. COLD REMEDIES MARKET FOR DRUG STORES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. COLD REMEDIES MARKET FOR SUPERMARKETS/HYPERMARKETS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. COLD REMEDIES MARKET FOR E-COMMERCE/ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: COLD REMEDIES MARKET
  • FIGURE 36. Top player positioning, 2022
  • FIGURE 37. RECKITT BENCKISER GROUP PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. RECKITT BENCKISER GROUP PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. RECKITT BENCKISER GROUP PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. PRESTIGE BRANDS HOLDINGS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. PRESTIGE BRANDS HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. PRESTIGE BRANDS HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. PROCTER AND GAMBLE CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. PROCTER AND GAMBLE CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. PROCTER AND GAMBLE CO.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Cold Remedies Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers